– Revenue of RMB 53.96 million mainly driven by the commercial launch of XPOVIO ® (selinexor) in Mainland China on May 13, 2022 – Adjusted loss reduced to RMB 126 million for the first six months of 2022 from RMB 210 million in the same period last year – Cash and bank balances of RMB…
Read More
